These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29195664)

  • 21. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
    Minor DR; Puzanov I; Callahan MK; Hug BA; Hoos A
    Pigment Cell Melanoma Res; 2015 Sep; 28(5):611-2. PubMed ID: 25996827
    [No Abstract]   [Full Text] [Related]  

  • 22. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
    Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.
    Uribe P; Anforth RM; Kefford RF; Fernandez-Peñas P
    Melanoma Res; 2014 Oct; 24(5):501-3. PubMed ID: 24922191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
    Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Esophageal actinomycosis.
    Chou FT; Cheng KS; Chiang IP
    Adv Ther; 2006; 23(4):623-6. PubMed ID: 17050504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spontaneous peritonitis attributed to actinomyces species.
    Flores-Franco RA; Lachica-Rodriguez GN; Banuelos-Moreno L; Gomez-Diaz A
    Ann Hepatol; 2007; 6(4):276-8. PubMed ID: 18007561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.
    Gonzalez-Cao M; Boada A; Teixidó C; Fernandez-Figueras MT; Mayo C; Tresserra F; Bustamante J; Viteri S; Puertas E; Santarpia M; Riso A; Barron F; Karachaliou N; Rosell R
    Oncotarget; 2016 Aug; 7(35):56619-56627. PubMed ID: 27447748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
    J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Actinomycosis].
    Stabrowski T; Chuard C
    Rev Med Suisse; 2019 Oct; 15(666):1790-1794. PubMed ID: 31599519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma.
    Garrido MC; Gutierrez C; Riveiro-Falkenbach E; Ortiz P; Rodriguez-Peralto JL
    Am J Dermatopathol; 2015 Oct; 37(10):795-8. PubMed ID: 26381028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omental actinomycosis imitating a foreign body infection.
    Choi YS; Park YG
    Z Gastroenterol; 2017 Jul; 55(7):675-678. PubMed ID: 28709171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
    Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
    Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma.
    Saint-Jean M; Le Moigne M; Daguze J; Bossard C; Peuvrel L; Quéreux G; Dréno B
    Acta Derm Venereol; 2018 Apr; 98(5):530-531. PubMed ID: 29362816
    [No Abstract]   [Full Text] [Related]  

  • 34. Rare lesions of the oral cavity: case report of an actinomycotic lesion limited to the gingiva.
    Sakallioğlu U; Açikgöz G; Kirtiloğlu T; Karagöz F
    J Oral Sci; 2003 Mar; 45(1):39-42. PubMed ID: 12816363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary actinomycosis of the breast caused by Actinomyces turicensis with associated Peptoniphilus harei.
    Abdulrahman GO; Gateley CA
    Breast Dis; 2015; 35(1):45-7. PubMed ID: 25095985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive sinonasal actinomycosis: case report and literature review.
    Vorasubin N; Wu AW; Day C; Suh JD
    Laryngoscope; 2013 Feb; 123(2):334-8. PubMed ID: 23008010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dabrafenib in the treatment of metastatic or unresectable melanoma.
    Khoja L; Hogg D
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):265-76. PubMed ID: 25711514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Agminated melanocytic nevus status post dabrafenib therapy for metastatic melanoma.
    Agulló A; Hinds B; Santesteban R; Mitxelena JM; Yanguas I
    Dermatol Online J; 2016 Jul; 22(7):. PubMed ID: 27617734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
    Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
    Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C
    J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.